Profile of infliximab in the treatment of pediatric Crohn's disease.
Profile of infliximab in the treatment of pediatric Crohn's disease.
复制标题
DOI：
10.2147/phmt.s64943
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Dadalski M
中科院分区：
文献类型：
--
作者：
Kierkus J;Szymanska E;Oracz G;Wiernicka A;Dadalski M
近年来，抗肿瘤坏死因子-α单克隆抗体的新型生物疗法彻底改变了克罗恩病的治疗。英夫利西单抗是第一种生物制剂，已被证明可显著改善临床和内镜结果。鉴于英夫利西单抗在克罗恩病治疗中的日益普及，我们回顾了该药物在儿科治疗该病中的作用。
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn’s disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.